Supplementary Table S3. Number of severe grade 3 or 4 adverse events in the 122 pediatric allo-HSCT patients ≤ 100 days post-transplant. Relationships between categorical variables are examined by crosstabulation and Fisher’s Exact test.

|                           | 0–1 grade 3 or 4 N (%) | ≥2 grade 3 or 4 N (%) | p-value |
|---------------------------|------------------------|-----------------------|---------|
| All patients              | 91 (75)                | 31 (25)               | 0.032   |
| Gender                    |                        |                       |         |
| Male                      | 62 (68)                | 14 (45)               |         |
| Female                    | 29 (32)                | 17 (55)               |         |
| Disease                   |                        |                       | NS      |
| Non-malignant             | 17 (19)                | 7 (23)                |         |
| Malignant                 | 74 (81)                | 24 (77)               |         |
| Diagnosis                 |                        |                       | 0.029   |
| ALL/NHL                   | 57 (63)                | 16 (52)               |         |
| AML/CML                   | 16 (18)                | 6 (19)                |         |
| SAA/FA/JMML/MDS/other hematopoietic | 9 (10) | 9 (29) |         |
| Immunological and metabolic disorder | 9 (10) | 0 |         |
| Donor                     |                        |                       | NS      |
| Sibling                   | 43 (47)                | 8 (26)                | 0.020   |
| MUD                       | 40 (44)                | 22 (71)               |         |
| Cord blood                | 5 (6)                  | 1 (3)                 |         |
| Family/haplo              | 3 (3)                  | 0                     |         |
| fTBI                      |                        |                       | NS      |
| No                        | 16 (18)                | 8 (26)                |         |
| Yes                       | 75 (82)                | 23 (74)               |         |
| Conditioning              |                        |                       | NS      |
| fTBI+MAC                  | 75 (82)                | 23 (74)               |         |
| No fTBI+MAC               | 10 (11)                | 7 (23)                |         |
| RIC                       | 6 (7)                  | 1 (3)                 |         |
| aGVHD                     |                        |                       | NS      |
| No                        | 33 (36)                | 9 (29)                |         |
| Yes                       | 58 (64)                | 22 (71)               |         |
| Grade 3–4 aGVHD           |                        |                       | 0.030   |
| No                        | 74 (81)                | 19 (61)               |         |
| Yes                       | 17 (19)                | 12 (39)               |         |
| Defibrotide               |                        |                       | NS      |
| No                        | 57 (63)                | 13 (42)               |         |
| Yes                       | 34 (37)                | 18 (58)               |         |
| Survival                  |                        |                       | 0.007   |
| Yes                       | 69 (76)                | 15 (48)               |         |
| No                        | 22 (24)                | 16 (52)               |         |

Abbreviations: fTBI = fractionated TBI, MAC = myeloablative conditioning, RIC = reduced intensity conditioning, aGVHD = acute GVHD